Extract of bacteria of the genus Sphingomonas
AssigneeL'oreal
InventorsKarima Labiad-Hadji, Cosima Dufour-Schroif, Gayané Azadiguian, Sylvie Bun
Life of this patent
Estimating the term…
Abstract
The present invention relates to an extract of bacteria of the genus Sphingomonas, and compositions comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas for use in the prevention and/or the treatment of cutaneous reactions caused by an allergic reaction and for use in the modulation of the immune response and optionally in the reinforcement of the barrier function of the skin.
Claims17
A method for preventing or treating cutaneous reactions caused by an allergic reaction comprising the administration of an extract from non-genetically modified bacteria of the species Sphingomonas xeophaga, wherein the extract:
- has an activity in activating the hTLR2 receptors and/or in promoting the expressions of genes related to the reinforcement of the barrier function of the skin;
- or
- has an activity in inhibiting the secretion of the pro-inflammatory mediator PGE2;
- or
- has an activity in stimulating the expression of IL-10 without significantly impacting the expression of IL-12, IL-6 and IL-8;
- or
- has an activity in inhibiting the production of IgE by B lymphocytes.
A method for preventing or treating cutaneous reactions caused by an allergic reaction comprising the administration of a composition comprising:
- a.—an extract from non-genetically modified bacteria of the species Sphingomonas xeophaga, or
- b.—at least one non-genetically modified bacterium of the species Sphingomonas xeophaga;
- wherein the extract:
- has an activity in activating the hTLR2 receptors and/or in promoting the expressions of genes related to the reinforcement of the barrier function of the skin;
- or
- has an activity in inhibiting the secretion of the pro-inflammatory mediator PGE2;
- or
- has an activity in stimulating the expression of IL-10 without significantly impacting the expression of IL-12, IL-6 and IL-8;
- or
- has an activity in inhibiting the production of IgE by B lymphocytes.
A method for modulating the immune response, comprising the administration of an extract from non-genetically modified bacteria of the species Sphingomonas xeophaga, wherein the extract:
- has an activity in activating the hTLR2 receptors and/or in promoting the expressions of genes related to the reinforcement of the barrier function of the skin;
- or
- has an activity in inhibiting the secretion of the pro-inflammatory mediator PGE2;
- or
- has an activity in stimulating the expression of IL-10 without significantly impacting the expression of IL-12, IL-6 and IL-8;
- or
- has an activity in inhibiting the production of IgE by B lymphocytes.
A method for modulating the immune response, comprising the administration of a composition comprising:
- a.—an extract from non-genetically modified bacteria of the species Sphingomonas xeophaga, or
- b.—at least one non-genetically modified bacterium of the species Sphingomonas xeophaga;
- wherein the extract:
- has an activity in activating the hTLR2 receptors and/or in promoting the expressions of genes related to the reinforcement of the barrier function of the skin;
- or
- has an activity in inhibiting the secretion of the pro-inflammatory mediator PGE2;
- or
- has an activity in stimulating the expression of IL-10 without significantly impacting the expression of IL-12, IL-6 and IL-8;
- or
- has an activity in inhibiting the production of IgE by B lymphocytes.
Dependencies are inferred from the claim text.